Events
Eyes On Glaucoma 2025 highlights advancements in disease care
Largest virtual glaucoma meeting of the year sees record attendance.
Pipeline
FDA agrees to Atsena's regulatory pathway for XLRS gene therapy
Expansion of LIGHTHOUSE study will support potential BLA submission in early 2028 to become the first FDA-approved treatment for the inherited retinal disease.
Business
4DMT cuts 25% of workforce and fast-tracks wet AMD gene therapy program
Company reports streamlined planning to advance phase 3 clinical trials of 4D-150, under evaluation to deliver a single, low-dose, and sustained multi-year intravitreal injection.
Pipeline
LENZ and Théa partner on Canadian commercialization of presbyopia eye drop
Licensing and commercialization agreement gives LENZ $70 million in upfront and milestone payments; news comes as company awaits FDA approval.
Business
Alcon to purchase LumiThera
Targeting a Q3 sale, acquisition includes Valeda Light Delivery System, the first and only PBM treatment for early-to-intermediate dry AMD.
Business
Eyenovia rebrands as Hyperion DeFi, Inc with new focus
Name change aligns with company's pivot toward decentralized finance and focus on a cryptocurrency treasury reserve strategy; plans remain to commercialize Optejet.
Events
Vision Expo shifting to single annual event in 2026
Starting next February in Orlando, the trade-only conference and exhibition will rotate its location throughout major U.S. cities moving forward.
Research
Surprising protective role of estrogen may lower glaucoma risk in women
Age at menopause had a significant effect on RNFL thickness among women.
Events
Happy 4th of July!
A word from the
Research
Diabetic patients may have worsening visual outcomes after orbital cellulitis
Study highlights susceptibility of diabetic patients to poor vision following orbital cellulitis.
Business
AOA inducts new leadership during 2025 Optometry's Meeting
Vowing pushback against vision plan abuses, Jacquie M. Bowen, OD, is named president as the 2025-2026 AOA Board of Trustees are inducted.
Products
Regener-Eyes ends recall of remaining older product inventory
Company previously issued voluntary recall for older bottles in December 2024 following the launch of updated bottles with backflow prevention technology.
Research
New data finds increased prevalence of refractive surgery among cataract patients
Clinicians may need to consider new ways of calculating IOL power due to prevalence of high myopia and previous refractive surgery.
Research
Bausch + Lomb unveils 2025 state of dry eye survey results
Building on 2024 findings, latest results indicate a need for more patient education to dispel ongoing misconceptions surrounding dry eye.
Pipeline
Opus Genetics' VEGA-3 presbyopia trial meets endpoints for phentolamine 0.75%
Topline data found a statistically significant number of patients achieved a ≥15-letter improvement in binocular DCNVA; H2 2025 NDA submission expected.
Research
AOA report analyzes ocular risks of GLP-1RAs
Released during the 2025 Optometry’s Meeting, this comprehensive rundown dives into potential rare ophthalmic side effects associated with use—and offers clinical care recommendations.
Business
ForSight Robotics raises $125M to advance robotic ophthalmic surgical platform
Financing to support expansion of ORYOM, the world’s first hybrid intraocular ophthalmic platform designed to deliver advanced capabilities beyond standard cataract surgery.
Research
Earlier diabetes diagnosis may lead to worsening DR progression
Study identifies mechanisms for the potential protective effect of later diabetes diagnosis on DR severity.
Events
Alcon offers first look at TRYPTYR, debuts new innovations for contact lens ordering app
Company announces partnership with Revolution EHR to advance its MARLO platform; highlights new dry eye and contact lens offerings.
Pipeline